Autolus Revenue and Competitors

London, UK

Location

$631.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Autolus's estimated annual revenue is currently $2.5M per year.(i)
  • Autolus's estimated revenue per employee is $5,426
  • Autolus's total funding is $631.7M.
  • Autolus's current valuation is $321.6M. (January 2022)

Employee Data

  • Autolus has 470 Employees.(i)
  • Autolus grew their employee count by 16% last year.

Autolus's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Finance/Chief Accounting OfficerReveal Email/Phone
3
Chief Accounting Officer (CAO), VP FinanceReveal Email/Phone
4
VP Organisation DevelopmentReveal Email/Phone
5
General CounselReveal Email/Phone
6
VP, Head Clinical OperationsReveal Email/Phone
7
VP Human ResourcesReveal Email/Phone
8
SVP Corporate DevelopmentReveal Email/Phone
9
Head IPReveal Email/Phone
10
VP Head QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Autolus?

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. We are building a leading biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours. Autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient's own cells.

keywords:N/A

$631.7M

Total Funding

470

Number of Employees

$2.5M

Revenue (est)

16%

Employee Growth %

$321.6M

Valuation

N/A

Accelerator

Autolus News

2022-04-13 - Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post ...

Autolus Therapeutics plc (NASDAQ:AUTL) Expected to Post Quarterly Sales of $260,000.00. Posted by admin on Apr 16th, 2022.

2022-04-13 - Autolus Therapeutics plc (NASDAQ:AUTL) Expected to ...

Autolus Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year-over-year growth...

2022-04-06 - Should You Buy Autolus Therapeutics PLC (AUTL) Stock Monday?

Autolus Therapeutics PLC (AUTL) stock has fallen -21.77% over the last 12 months, and the average rating from Wall Street analysts is a...

2021-11-07 - Blackstone to Invest Up to $250 Million in Autolus Therapeutics of U.K.

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said. Of the total investment, as much as $150 million will support the develop ...

2021-06-30 - Autolus Therapeutics : Consolidated Financial Statements (Form 6-K)

Registered Number 11185179 (England & Wales) Annual Report and Accounts for the year ended 31 December 2020 for Autolus Therapeutics pie AUTOLUS THERAPEUTICS PLC Introduction and Contents Autolus Therapeutics pie (the 'Company', or 'Parent Company') is a public limited company incorporate ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M4705%N/A
#2
$170.7M4717%N/A
#3
$120.7M4717%N/A
#4
$129.8M4723%N/A
#5
$134.2M4737%N/A